Trials / Completed
CompletedNCT01756248
EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
Special Drug Use Investigation of EYLEA for AMD
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,872 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD). The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice. A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321) | Patients treated with EYLEA under practical manner for AMD. |
Timeline
- Start date
- 2012-12-26
- Primary completion
- 2018-12-31
- Completion
- 2019-05-20
- First posted
- 2012-12-25
- Last updated
- 2023-06-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01756248. Inclusion in this directory is not an endorsement.